High-Sensitivity Proteomic Analysis Services Using Dual Recognition and Next-Generation Sequencing (PEA or Equivalent) DNA Detection Technologies for 172 Samples from Lung Cancer Patients

This tender concerns the procurement of high-sensitivity proteomic analysis services for 172 samples collected from lung cancer patients. The services must utilize advanced technologies, specifically dual recognition and Next-Generation Sequencing (NGS) based DNA detection, or equivalent methods. The objective is to perform detailed proteomic analysis to gain deeper insights into lung cancer, potentially identifying biomarkers, understanding disease mechanisms, or evaluating treatment responses. The selected service provider will be responsible for the comprehensive analysis of the provided patient samples, employing state-of-the-art techniques to ensure high accuracy and sensitivity. This procurement is crucial for advancing research and clinical understanding of lung cancer, supporting diagnostic, prognostic, or therapeutic developments. The tender specifies the need for specialized expertise and advanced laboratory capabilities to handle complex proteomic and genomic analyses, ensuring the reliability and validity of the results obtained from the patient cohort.

This is a services contract in the Research sector, with a focus on Laboratories. Located in Romania, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for services in the Research sector. Service contracts are typically evaluated on both technical quality and price, and may require bidders to demonstrate relevant experience and qualified personnel. This contract has already been awarded. The information is published for transparency and market intelligence purposes.